| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(11 years ago) | |
| US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(11 years ago) | |
| US5688819 | ABBVIE | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug, 2014
(9 years ago) | |
| US8299118 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US9241918 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8278353 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8933127 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8933120 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8309605 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8586630 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8524777 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US9155716 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8338479 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8772338 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
Lumigan is owned by Abbvie.
Lumigan contains Bimatoprost.
Lumigan has a total of 15 drug patents out of which 3 drug patents have expired.
Expired drug patents of Lumigan are:
- US6403649
- US8017655
- US5688819
Lumigan was authorised for market use on 16 March, 2001.
Lumigan is available in solution/drops;ophthalmic dosage forms.
Lumigan can be used as method of treating glaucoma or elevated intraocular pressure, a method of treating a patient with glaucoma or ocular hypertension, a method of lowering intraocular pressure, lumigan is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension, method of treating glaucoma in a patient, a method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension, topical treatment of ocular hypertension and glaucoma, reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.
The generics of Lumigan are possible to be released after 13 June, 2027.
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 16 March, 2001
Treatment: Lumigan is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Topical treatment of ocular hypertension and...
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIGAN family patents
